IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes po

Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess,

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter financial results on Thursday. The tr

Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 mi

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed t

– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pedi

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 m

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which met the

 Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TV

Citizens analyst Jason N. Butler maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Market O

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 m

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.01) per share which missed t

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-We

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were update

Ironwood Pharmaceuticals (IRWD) stock rose with high volume on Friday, releasing financial guidance

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-We

Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2025 sales outlook from $260.000 million-$290.000 mi

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which beat the

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-children-7-years-and-older-i

Ironwood Pharmaceuticals (NASDAQ:IRWD) sees FY2025 sales of $260.000 million-$290.000 million vs $27

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.14 per share which beat the

Wells Fargo analyst Mohit Bansal downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Overweigh

Jefferies analyst Amy Li downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Buy to Hold and l

Leerink Partners analyst Faisal Khurshid maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a

Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong